ORPHENADRINE CITRATE
Generic: ORPHENADRINE CITRATE
Hikma Pharmaceuticals USA Inc.Manufacturer
INTRAMUSCULAR, INTRAVENOUSRoute
ORPHENADRINE CITRATEActive Substance
2003-03-04Original Approval
ORPHENADRINE CITRATE is FDA application ANDA040463, sponsored by HIKMA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2022-03-21
Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton,CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.
Class III2014-07-11
Orphenadrine Citrate Extended Release Tablets, 100 mg a)100-count bottle, (NDC 0185-0022-01) b) 1000-count bottle, (NDFailed Dissolution Specifications: Product found to be out of specification (OOS) during stability t
Top Reported Reactions
1
PAIN
67 reports
2
NAUSEA
54 reports
3
FATIGUE
49 reports
4
ANXIETY
46 reports
5
DRUG INEFFECTIVE
45 reports
6
ARTHRALGIA
41 reports
7
HEADACHE
40 reports
8
DIARRHOEA
38 reports
9
DIZZINESS
38 reports
10
VOMITING
32 reports